by Dale Harrison | Jul 2, 2021 | Publications
“Meso-tetra (4-carboMeso-tetra (4-carboxyphenyl) porphyrin (TCPP) is taken up in cancer cells by the CD320 receptor” International Conference on Porphyrins and Phthalocyanines (ICPP) ICPP-11, June 26 through July 2, 2021 Authors David J. Elzi, William E. Bauta,...
by Dale Harrison | Jun 25, 2021 | Publications
“Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 – 25, 2021 Authors David J. Elzi, William E. Bauta,...
by Dale Harrison | May 22, 2021 | Publications
“Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells” At the American Association of Cancer Research (AACR) Annual Meeting 2021, April-May, 2021 Authors David J. Elzi, William Bauta,...
by Dale Harrison | Feb 25, 2021 | Publications
“Identification of a novel mechanism for meso‐tetra (4‐carboxyphenyl) porphyrin (TCPP) uptake in cancer cells” Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021 Authors David J. Elzi, William E....
by Dale Harrison | Jan 16, 2021 | Publications
“Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity” International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, Jan. 2021 Authors Lydia H. Bederka1,...
by Dale Harrison | Dec 14, 2020 | Publications
“Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin-mediated endocytosis, Poster Presentation” American Society of Cell Biology’s Cell Bio Virtual 2020; Cancer Therapy: Defining Therapeutic Targets...
